News
SYRS
0.2626
-10.44%
-0.0306
Weekly Report: what happened at SYRS last week (1118-1122)?
Weekly Report · 8h ago
BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
Reuters · 6d ago
Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
Benzinga · 11/18 12:34
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
TipRanks · 11/18 12:27
SYROS PHARMACEUTICALS INC - APPOINTMENT OF GERALD QUIRK, ESQ., AS PRESIDENT & CEO
Reuters · 11/18 12:04
SYROS PHARMACEUTICALS INC - EXPECTS THAT WORKFORCE REDUCTION WILL BE SUBSTANTIALLY COMPLETE BY DECEMBER 6
Reuters · 11/18 12:04
SYROS - NOTIFIED CONLEY CHEE,CEO ,JASON HAAS,CFO, DAVID ROTH, CHIEF MEDICAL OFFICER THAT EMPLOYMENT OF SUCH OFFICERS WILL TERMINATE WITHOUT CAUSE
Reuters · 11/18 12:04
Weekly Report: what happened at SYRS last week (1111-1115)?
Weekly Report · 11/18 09:01
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11/14 16:29
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
NASDAQ · 11/14 15:24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/13 21:05
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results
Benzinga · 11/13 19:02
BUZZ-U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
Reuters · 11/13 18:43
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
Benzinga · 11/13 17:45
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Benzinga · 11/13 17:11
Syros cut to neutral by H.C. Wainwright on failed drug study
Seeking Alpha · 11/13 16:51
BUZZ-U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Reuters · 11/13 16:01
US Stocks Mixed; Inflation Rate Increases In October
Benzinga · 11/13 15:02
BUZZ-Syros falls after blood cancer drug fails in late-stage trial
Reuters · 11/13 14:02
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure
Dow Jones · 11/13 13:14
More
Webull provides a variety of real-time SYRS stock news. You can receive the latest news about Syros Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).